Closed
NORD Rare Disease Grant Program
Appendiceal cancer research funding
Record updated
- Funding available
- $ 50,000
- Deadline
- Unspecified
- Location
- Canada
Overview
The Appendix Cancer and Pseudomyxoma Peritonei (ACPMP) opportunity from NORD supports two $50,000 US awards for researchers and clinicians in the United States and internationally. It funds basic scientific, clinical, or translational research on appendiceal cancer and pseudomyxoma peritonei, including studies of biology, genetics, and pharmacology.
At a glance
Funding available
- Maximum funding
- $50,000
- Conduct research and development activities
- Conduct research or evaluation activities
Eligible candidates
- Location
- Canada
- Eligible Industries
- All industries
- Annual revenue
- All revenue ranges
- Organisation size
- All organization sizes
- Audience
- All groups
- Legal structures
- Non-profit
Non-profit candidates
- Sector of operation
- Research
- Target groups
- Nonprofits / charities, Academia / students
- Revenue structures
- 100% donations / grants
- Scope
- International
Receipt of requests is now closed
Get notified about updates to this grant.
Availability timeline
2026
Periods: 1
Eligibility
Who is eligible?
- Researchers
- Clinicians
- Researchers both within the United States and internationally
Eligible expenses
- Staff salary
- Technical assistance
- Supplies
- Small equipment
Ineligible Costs and Activities
- Principal investigator salary
- Overhead
- Indirect costs
Eligible geographic areas
- International
Activities funded
- Basic scientific, clinical, or translational research on appendix cancer and/or appendiceal pseudomyxoma peritonei.
- Studies of the biology, epidemiology, genetics, pharmacology, immunobiology, or biochemistry of malignant epithelial neoplasms of the appendix.
- Research with potential to yield diagnostic, therapeutic, or population-based advances.
How to apply
- Complete the requested information directly in the provided document and/or merge any additional required documents into a single PDF file.
- Submit a completed application and letter of intent electronically to research-programs@rarediseases.org with NORD Letter of Intent as the subject line.
- Ensure all applications are received by October 12, 2025 (11:59 pm PT).
Documents Needed
- Application summary
- Letter of Intent, maximum length 2 pages
- Biographical sketch and bibliography for the principal investigator
- List of co-investigators, if applicable
- Budget outline
Selection criteria
- Awards are based solely on scientific merit.
- Consideration is given to the potential to translate research into extramural funding applications, additional pre-clinical studies, and clinical trials.
- The innovation of the proposal and its alignment with the goals of the grant program are considered.
- Protocol design, objectiveness of parameters measured, and statistical evaluation proposed are reviewed.
- Strong preference is given to researchers holding a faculty-level appointment or senior scientific position at an academic or non-profit institution or foundation, unless indicated in the RFP.
Processing and Agreement
- Letters of intent are reviewed by NORD reviewers, and finalists are invited to submit full proposals.
- Requests for full proposals will be issued via email in late December 2025.
- Award announcements will be made via email and posted on NORD’s website in May 2026.
- Funding begins after all necessary documents, such as IRB forms, patient consent forms, and signed grant agreements, have been received by NORD; if human or animal subjects are involved, copies of governance documents are required from each site before payment can be issued, and compliance with international funding regulations must be confirmed when applicable.
- Awarded investigators must submit financial and scientific progress reports every six months.
Additional information
- Clinical drug trials must meet requirements established by the U.S. Food & Drug Administration (FDA).
- International applicants are responsible for all document translations.
- Letters of support from an individual advocate (e.g., patient, care partner) or patient advocacy group in this disease space are optional but encouraged.
Contacts
Official sources
Frequently Asked Questions about the NORD Rare Disease Grant Program Program
What is the NORD Rare Disease Grant Program?
The Appendix Cancer and Pseudomyxoma Peritonei (ACPMP) opportunity from NORD supports two $50,000 US awards for researchers and clinicians in the United States and internationally. It funds basic scientific, clinical, or translational research on appendiceal cancer and pseudomyxoma peritonei, including studies of biology, genetics, and pharmacology.
How much funding can be received?
NORD Rare Disease Grant Program Funds up to $50,000 of admissible expenses.
Who is eligible for the NORD Rare Disease Grant Program program?
To be eligible for the NORD Rare Disease Grant Program program, you must:
The principal investigator must have sufficient education and experience.
The project must be basic scientific, clinical, or translational research.
The research must focus on appendix cancer and/or appendiceal pseudomyxoma peritonei.
What expenses are eligible under NORD Rare Disease Grant Program?
Staff salary
Technical assistance
Supplies
Small equipment
Who can I contact for more information about the NORD Rare Disease Grant Program?
You can contact Foundation for Angelman Syndrome Therapeutics (FAST) by email at research-programs@rarediseases.org.
Where is the NORD Rare Disease Grant Program available?
The NORD Rare Disease Grant Program program is available across Canada.
Is the NORD Rare Disease Grant Program a grant, loan, or tax credit?
NORD Rare Disease Grant Program is a Grant and Funding